Pancreatic cancer is one of the deadliest cancers with rapid disease progression.
Aiming to uncover the nature of DF, we performed a quantitative secretomic analysis of the conditioned media of these 2 cell lines. 10 It is noteworthy that some secretory proteins are secreted as the cargo of extracellular vesicles. Exosomes are small (30-100 nm) extracellular vesicles derived from multivesicular bodies containing and transporting cargos, such as proteins, noncoding RNAs and DNAs, 11 and are released by multiple cell types acting as message carriers during intercellular communication. 12, 13 Exosomes have been reported to play multiple roles during cancer progression, such as the formation of a premetastatic niche, determination of organotropic metastasis, promotion of epithelial-mesenchymal transition, regulation of the local microenvironment, and transportation of oncogenic proteins. [14] [15] [16] [17] [18] [19] [20] [21] Exosomal proteins are more stable and detectable than regular secretory proteins in body fluids, which makes them perfect candidates as novel biomarkers. [22] [23] [24] Combining our previous studies and the reported functions of exosomes, we hypothesize that the exosomes from PC-1.0 cells are more enriched in key proteins promoting cancer progression and could transport these oncogenic proteins to PC-1 cells. Furthermore, the enriched exosomal proteins of PC-1.0 may serve as novel biomarkers for pancreatic cancer.
In this study, utilizing in vitro cellular assays, we showed that PC-1.0-derived exosomes could be taken up and enhance the proliferation, migration and invasion abilities of PC-1 cells. Proteomic and bioinformatic analyses of the differential exosomal proteins between PC-1.0 and PC-1 showed that PC-1.0-derived exosomes were more enriched in proteins that play key roles in cancer progression. The zinc transporter protein ZIP4 was the most upregulated protein in PC-1.0-derived exosomes. ZIP4 is a membranelocated (plasma membrane, endosome membrane and extracellular vesicle membrane) zinc ion transporter regulating intracellular zinc homeostasis. ZIP4 is reported to be differentially expressed in multiple cancers and to be closely related to the progression of cancer, including pancreatic cancer. [25] [26] [27] [28] [29] [30] [31] [32] [33] In vitro and in vivo studies have shown that exosomal ZIP4 can significantly promote pancreatic cancer growth. Using clinical blood samples from patients with malignant pancreatic cancer, patients with benign pancreatic disease, patients with biliary disease and healthy subjects, for the first time,
we showed the efficacy of exosomal ZIP4 as a novel diagnostic biomarker for pancreatic cancer.
| MATERIALS AND METHODS

| Ethics approval and consent to participate
This study was approved by the local ethics committee of the Affili- 
| Cell lines and cell culture
Two hamster pancreatic cancer cell lines were used as follows: PC-1.0 (highly malignant) and PC-1 (moderately malignant). The PC-1 cell line was established from pancreatic ductal adenocarcinomas induced by (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluophosphate (BOP) in a Syrian golden hamster. The PC-1.0 cell line was established from a subcutaneous tumor produced after the inoculation of a hamster with PC-1 cells. 34 The human pancreatic cancer cell lines AsPC-1 and Capan-2 were purchased from the American Tissue Culture Collection (Rockville, MD, USA). Cells were incubated as previously described. tions. The supernatants were purified in advance using Amicon Ultra15 100K ultrafilter devices (Millipore, Billerica, MA, USA) to remove nonexosomal proteins. For proteomic analysis and electron microscopy, the initial pellet was resuspended in sterile PBS. The resuspended pellet was isolated again with an ExoQuick-Tc Kit using the same procedure to further remove nonexosomal proteins.
| Electron microscopy
The sample preparation was performed as described previously. 35, 36 In brief, isolated exosome pellets were fixed with 2.5% glutaraldehyde and washed twice with PBS. The pellets were then stained with aqueous phosphotungstic acid and fixed on copper mesh Formvar grids. The samples were observed with a HITACHI H-7650 transmission electron microscope (HITACHI, Tokyo, Japan).
| Western blot assay
Western blotting was performed as described previously. 4 Samples of equivalent total protein (20 μg) were loaded. Primary antibodies against CD63, CD81, HSP70 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), β-Actin, ZIP4, Adiponectin, MMP9 and MMP12 (ProteinTech Group, Rosemont, IL, USA) were used.
| Fluorescent labeling of exosomes
The exosomal proteins were labeled fluorescent green with ExoGlow (System Biosciences) according to the manufacturer's protocol.
Further consecutive visualization with fluorescence microscopy was performed for 24 hours.
| Cell proliferation assay
Cell proliferation assays were performed using a Cell Counting Kit-8
(CCK-8, Dojindo Molecular Technologies, Tokyo, Japan) according to the manufacturer's protocol. Exosomes equaling 500 ng of exosomal proteins were added per well if needed.
| In vitro migration assay
Wound-healing migration assays were performed as described in our previous studies. 10 Exosomes equaling 10 μg of exosomal proteins were added to the culture medium if needed.
| In vitro invasion assay
Invasion assays using the Transwell system (24 wells, 8-μm pore size filters, Costar, New York, USA) were performed as described in our previous studies. 10 Exosomes equaling 5 μg of exosomal proteins were added to the upper chamber together with the cells if needed.
| Protein digestion and isobaric tags for relative and absolute quantification labeling
Protein digestion was performed according to the standard procedure, and the resulting peptide mixture was labeled using 4-plex or 8-plex iso- 
| High pH reverse-phase liquid chromatography separation
The samples were fractionated using high pH reversed-phase separation to increase proteomic depth. The peptides were resuspended in the loading buffer (5 mmol/L ammonium formate containing 2% acetonitrile, pH 10) and separated by high pH reversed-phase liquid chromatography (RPLC, Acquity Ultra Performance LC, Waters, Milford, USA). The gradient elution was performed on a high pH RPLC column (C18, 3.5 μm, 150 × 2.1 mm, Waters) at 200 μL/min with the gradient increasing for 60 minutes. Twenty fractions were collected from each sample and were subsequently pooled, resulting in 10 total fractions per sample.
| Liquid chromatography tandem mass spectrometry
The experiments were performed on a Q Exactive mass spectrometer, which was coupled to the Easy-nLC system. Ten microliters of each fraction were injected for nanoLC-MS/MS analysis. The peptide mixture (2 μg) was loaded onto a C18-Reversed-Phase Column 
| shRNA design and plasmid transfection
The shRNA plasmids specific for ZIP4 were purchased from Gene- 
| Cell cycle assay by flow cytometry
Cell cycle analysis was performed using a detection kit (Nanjing KeyGen Biotechnology, Nanjing, China) according to the manufacturer's protocol. Exosomes equaling 10 μg of exosomal proteins per well were added if needed.
| Animal studies
Subcutaneous tumor models were generated using 4-week-old female BALB/c nude mice (Huafukang Biotechnology, Beijing, China).
The mice were kept and fed in a specific-pathogen-free level animal laboratory of Shengjing Hospital. A total of 1 × 10 6 PC-1 cells in .1-mL PBS were subcutaneously injected into the right axilla area. Ten days after the initial implantation, when the subcutaneous tumors were visible, the mice were injected with 60-μL PBS containing 30-μg normal PC-1.0-derived exosomes or ZIP4-knockdown exosomes in the implantation area twice a week. The size of the subcutaneous tumor was recorded twice a week with a Vernier caliper.
The volume of the tumor was calculated using the following equa-
/2, where L = tumor long axis and W = tumor short axis. All the measurements were repeated 3 times.
Four weeks from the initial implantation, the mice were killed, and the tumor tissues were surgically excised and measured.
| Immunohistochemical assay
Immunohistochemical staining of the tumor tissue was performed according to the kit manufacturer's protocol (Zhongshan Golden Bridge, Beijing, China) on 4% paraformaldehyde-fixed, paraffinembedded 4-μm tissue sections, which were later evaluated by 2 different specialists.
| Exosome isolation from human serum
For human serum samples, whole blood samples were collected from clinical routine blood tests and were stored for 1 hour at 4°C to be ). *P < .05; **P < .01; ***P < .001
Bioinformatic analysis of whole and differentially expressed exosomal proteins from PC-1.0 and PC-1 cells. A, Gene ontology (GO) analysis of whole exosomal proteins. B, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of whole exosomal proteins. C, GO analysis of differential exosomal proteins (protein abundance ratios with at least 1.5-fold change). D, KEGG analysis of differentially expressed exosomal proteins. *P < .05; **P < .01; ***P < .001 fully coagulated before being centrifuged at 2600 g at 4°C for 10 minutes. The supernatants were collected and stored in a −80°C
freezer for a maximum of 6 months. The exosomes were isolated from human serum samples with an ExoQuick Exosome Precipitation Kit (System Biosciences) according to the manufacturer's protocol.
| Enzyme-linked immunosorbent assay
The ZIP4 protein level of serum-derived exosomes was tested using a human ZIP4 ELISA kit (Cloud-Clone, Wuhan, China) according to the manufacturer's protocol. One hundred microliters of exosome samples (isolated from 250 μL of serum samples and resuspended in 200-μL PBS) was analyzed, and the protein concentration was calculated in comparison with a protein standard curve.
| Bioinformatic and statistical analyses
The following publicly available databases were utilized for the bioin- 3 | RESULTS
| PC-1.0-derived exosomes could be taken up and enhance PC-1 cell proliferation, migration and invasion abilities
According to the purpose of the experiments in this study, we applied different exosome isolation procedures ( Figure 1A ). In the in vitro cul- Figure S2) .
Furthermore, GO and KEGG pathway analyses were performed to database. Analysis by GEPIA showed that SLC39A4 (a gene encoding ZIP4 in humans) was highly expressed in multiple cancers, including pancreatic cancer ( Figure 3D ). Analysis by UALCAN showed that ZIP4 was differentially expressed in cases with different stages of pancreatic cancer, pancreatitis status and healthy subjects ( Figure 3E -G). 40 Cases with higher expression levels of ZIP4 showed worse survival rates than cases with lower expression levels ( Figure 3H ). Analysis by cBioPortal showed that cases with alterations in SLC39A4 were associated with less progression/diseasefree time than those without, indicating that ZIP4 was closely correlated with pancreatic cancer progression ( Figure 3I ). 
CONFLI CT OF INTEREST
The authors declare no conflict of interest for this article. 
